What is Achieve Life Sciences?
Achieve Life Sciences operates as a specialty pharmaceutical entity dedicated to the development and commercialization of cytisinicline, a therapeutic agent designed to combat nicotine addiction and smoking-related health issues. By focusing on a high-impact, unmet medical need, the company occupies a unique niche in the biotech landscape. Its business model centers on rigorous clinical validation and the pursuit of regulatory approvals to bring effective cessation treatments to a global market, thereby addressing one of the most persistent public health challenges of the modern era.
How much funding has Achieve Life Sciences raised?
Achieve Life Sciences has raised a total of $85M across 2 funding rounds:
Debt
$25M
Other Financing Round
$60M
Debt (2021): $25M with participation from Silicon Valley Bank
Other Financing Round (2024): $60M led by Propel Bio Partners, Nantahala Capital Management, and Sopharma
Key Investors in Achieve Life Sciences
Propel Bio Partners
Propel Bio Partners supports entrepreneurial life science companies by advancing groundbreaking technologies and therapies that enhance human health through a combination of scientific and business expertise.
Nantahala Capital Management
Nantahala Capital Management is a fundamentally-driven investment firm specializing in micro-cap stocks, applying a private equity-style approach to foster long-term growth in its portfolio companies.
Sopharma
Sopharma is a major established manufacturer of medicines with extensive expertise in phytochemistry and a strong commitment to Good Manufacturing Practice standards.
What's next for Achieve Life Sciences?
With the recent infusion of capital, Achieve Life Sciences is expected to prioritize the advancement of its clinical pipeline and the optimization of its manufacturing processes. The strategic focus will likely shift toward achieving key regulatory milestones and preparing for potential commercialization efforts. By aligning with experienced institutional backers, the company is poised to enhance its operational efficiency and strengthen its competitive moat in the specialty pharma space. Future growth will be contingent upon the successful execution of its late-stage clinical trials and the ability to effectively navigate the complexities of the global pharmaceutical market.
See full Achieve Life Sciences company page
